Eligibility Criteria

COVID-19 Vaccine
 

COVID-19 Vaccine Eligibility Criteria


All people in Manitoba aged 6 months and older are eligible for COVID-19 vaccination. This page provides information about vaccine eligibility and recommendations on the type of vaccine people should receive. If you have questions about your individual circumstances, including your individual risks and benefits of vaccination, please speak with your health care provider.

Canada's National Advisory Committee on Immunization (NACI) makes COVID-19 vaccine specific recommendations for people of all ages. These recommendations and guidance from NACI are available here.

You can also review the information below in this table developed by Manitoba Health, which shows the recommended mRNA immunization schedule based on age.


On this page


Other important information

You can make your vaccine appointment at some sites online or by calling 1-844-626-8222. The vaccine is also available from medical clinics, pharmacies and other locations. Use the Vaccine Finder to find a convenient location.

It's helpful to know when you received your previous doses of COVID-19 vaccine and the type of vaccine you received. If you do not recall this information and you have a Manitoba health card, you can locate it at: sharedhealthmb.ca/covid19/test-results/. If your immunization record is incomplete or incorrect, or you received a COVID-19 vaccination outside of Manitoba, you can have your file updated by completing and submitting this e-form.

You will need to complete a consent form for every COVID-19 vaccine you receive. Filling out the form in advance can make it faster for you to get your vaccine. Click here to fill out and print your consent form.




Children aged 6 months to 4 years


All children in this age group are eligible to receive a primary COVID-19 vaccine series of Moderna vaccine. A primary series consists of two doses. Booster doses are not available for this age group at this time.

Children must be at least six months of age at the time of their immunization appointment.

The interval between first and second doses for most children is eight weeks. Parents/guardians who want their child to receive their second dose sooner (after 28 days but before eight weeks) should discuss the risks and benefits with their immunizer or health care provider before vaccination, to ensure the parent/guardian understands the risks of an earlier second dose. A longer time period between doses provides a stronger immune response.

For more information on NACI recommendations, please go to the Canadian Immunization Guide.




Children aged 5 to 11


Children in this age group are eligible to receive a primary COVID-19 vaccine series and a first booster dose.

The pediatric Pfizer vaccine is the preferred vaccine for the primary series

For those who are 5 years old (before their sixth birthday), it is recommended to receive the pediatric Pfizer vaccine, but alternatively they can receive the infant Moderna vaccine.

Children must be five years old at the time of their immunization appointment. The recommended time between first and second doses for most children is eight weeks.

Parents/guardians who want their child to receive their second dose sooner (after 21 days but before eight weeks) should discuss the risks and benefits with their immunizer or health care provider before vaccination. This will ensure the parent/guardian understands the risks of an earlier second dose as a longer time period between doses provides a stronger immune response.

For children living in First Nations communities, the recommended time between first and second doses is 21 days for the pediatric Pfizer vaccine and 28 days for the Moderna vaccine.

Children ages 5 to 11 are now eligible to receive a booster dose with the pediatric Pfizer COVID-19 vaccine. The minimum interval between the primary series and a booster dose is 6 months.

The National Advisory Committee on Immunization (NACI) recommends:




Youth aged 12 to 17


It is recommended that youth in this age group receive a primary COVID-19 vaccine series and booster doses. A primary series consists of two doses of an mRNA COVID-19 vaccine.

The time between first and second dose is eight weeks. Individuals who wish to receive their second dose sooner (after 28 days but before eight weeks) should discuss the risks and benefits with their immunizer or health care provider before vaccination. Doing so ensures they understand the risks of an earlier second dose as a longer time period between doses provides a stronger immune response.

Youth aged 12 to 17 are recommended to receive the Pfizer vaccine for all doses in their primary series, due to a lower risk of myocarditis/pericarditis with this vaccine as compared to the Moderna vaccine in this age group.

The National Advisory Committee on Immunization (NACI) recommends:

This age group is eligible to receive a booster dose six months from their last dose of COVID-19 vaccine. However, individuals who meet the criteria can receive a booster dose after a minimum of three months.

It is also recommended for individuals to wait six months since their last COVID-19 infection. At minimum, they need to be fully recovered before receiving a booster dose.

At this time, youth age 12 to 17 are not eligible for the bivalent booster dose..




Adults aged 18 years and older


It is recommended that all adults aged 18 and older receive a primary COVID-19 vaccine series and booster doses.

A primary series consists of two doses. The time between the first and second dose is 8 weeks. Individuals who wish to receive their second dose sooner (after 28 days but before eight weeks) should discuss the risks and benefits with their immunizer or health care provider before vaccination. Doing so ensures they understand the risks of an earlier second dose as a longer time period between doses provides a stronger immune response.

For the primary series, it is recommended to get the same mRNA vaccine, if available. However, getting a combination of mRNA vaccines is both safe and effective, and either (Pfizer or Moderna) can be offered if:

Individuals must complete their primary series before they can receive a booster dose. It is recommended to wait six months from the last dose of vaccine. However, individuals who meet the criteria can receive a booster dose after a minimum of three months.

It is also recommended for individuals to wait six months since their last COVID-19 infection. At minimum, they need to be fully recovered before receiving a booster dose.

There are two types of booster doses available in Manitoba:

  1. Monovalent (Pfizer/Comirnaty™ and Moderna/Spikevax™) are the original mRNA vaccines which were designed to protect against the initial strain of the COVID-19 virus
    • All adults are eligible to receive a monovalent booster dose of COVID-19 vaccine. For this age group, either mRNA vaccine (Pfizer or Moderna) can be given, regardless of the COVID-19 vaccines previously received
  2. Bivalent (Moderna/Spikevax™/Bivalent (Original/Omicron) has been developed to protect against the original strain of COVID-19 as well as the BA.1 Omicron variant. This type of vaccine provides a broader immune response and may also protect against future variants of concern.
    • Health Canada has approved the use of the Moderna/SpikevaxTM Bivalent (Original/Omicron) vaccine as a booster dose for individuals 18 years of age and older.
    • It is recommended that all adults receive a bivalent booster dose as soon as they are eligible since this vaccine protects against multiple strains of the COVID-19 virus.

As of Sept. 22, all adults are eligible for a bivalent booster dose. The bivalent is recommended because it provides additional protection from COVID-19.




Infants, Children, Youth and Adults who are Moderately to Severely Immunocompromised


For the purposes of COVID-19 vaccine recommendations, the following individuals are considered moderately to severely immunocompromised due to a medical condition and/or treatment:


The following people should talk to their doctor to see whether they are considered to be immunocompromised:


Infants, children, youth and adults who are moderately to severely immunocompromised are recommended to receive a primary series of COVID-19 vaccine that consists of three doses. The interval between the first and the second dose is eight weeks.

Individuals who wish to receive their second dose sooner (after 28 days but before eight weeks) should discuss the risks and benefits with their immunizer or health care provider before vaccination, to ensure they understand the risks of an earlier second dose. A longer time period between doses provides a stronger immune response. The third dose in the primary series requires a prescription if given outside of a physician or pharmacists office and must be given at least 28 days after the second dose.

Children, youth and adults are eligible to receive additional booster doses. For moderately to severely immunocompromised people, the first booster dose would be their fourth dose. NACI recommends that all individuals 12 to 64 years of age who are at increased risk of severe illness from COVID-19, should be offered a fall COVID-19 vaccine booster dose regardless of the number of booster doses previously received.

It is recommended to wait six months from the last dose of vaccine. However, for immunocompromised individuals aged 12 years and older, they can get a booster dose earlier with a minimum interval of three months after their last dose.

It is also recommended for individuals to wait six months since their last COVID-19 infection. At minimum, they need to be fully recovered before receiving a booster dose.

Refer to the appropriate section above for more information on booster doses for children, youth and adultss.




Immunization after a COVID-19 infection


It is possible that people will get COVID-19 before starting or completing their COVID-19 vaccine primary series. In this case, it is recommended to wait two months before getting your next dose in the primary series.

If someone gets COVID-19 before getting their booster dose, it is recommended to wait six months before receiving their booster dose. At minimum, they need to be symptom free and no longer isolating before receiving a booster dose.

Recommendations may be different if you are moderately to severely immunocompromised. Please speak to your health care provider to get the best advice on when to get your next vaccine dose after a COVID-19 infection.

For more information on NACI's recommendation on interval between infection and getting your next COVID-19 vaccine dose, please visit: COVID-19 vaccine: Canadian Immunization Guide - Canada.ca.

 


 

Recommended mRNA Immunization Schedule


This table shows the recommended mRNA immunization schedule for people based on their age.

 

Approved COVID-19 mRNA vaccine

Time between 2 doses of primary series

Immunocompromised: Time between 3 doses of primary series

Time between most recent dose and any booster dose

Infants and children aged 6 months to 4 years

Moderna (25mcg)

8 weeks

4 to 8 weeks between each dose

Not eligible

Children aged 5 years *

Pfizer (10mcg) or

Moderna (25mcg)

8 weeks

4 to 8 weeks between each dose

6 months^

 

Children aged 6 to 11 years *

Pfizer (10mcg) or

Moderna (50mcg)

8 weeks

4 to 8 weeks between each dose

6 months^

 

Youth aged 12 to 17 years *

Pfizer (30mcg) or

Moderna (100mcg)

8 weeks

4 to 8 weeks between each dose

6 months

Adults aged 18 to 29 years *

Pfizer (30mcg) or

Moderna (50mcg/100mcg)

8 weeks

4 to 8 weeks between each dose

6 months

Adults aged 30 years and older

Pfizer (30mcg) or

Moderna (50mcg/100mcg)

8 weeks

4 to 8 weeks between each dose

6 months

 

* Pfizer is the recommended mRNA vaccine for the primary series in individuals aged 5 to 29 years.

 

^ Pfizer is the only vaccine approved for booster dose in this age group.

Note: Moderna 100mcg is offered as a primary series to individuals age 12 and older and as a first booster dose to individuals at increased risk of severe illness. Moderna 50mcg is offered as a booster dose to individuals age 12 and older who are not at risk of severe illness.